CytoGenix, Inc. Files US Patent Application for Family of DNA Antimicrobial Agents.HOUSTON -- CytoGenix, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) announces filing of a patent application with the US Patent and Trademark Office for an invention titled "Nucleotides for Prevention and Treatment of Microbial-Based Pathologies." Over the past two years, CytoGenix scientists have conducted numerous studies showing that DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. compounds are effective against bacterial pathogens including E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. and resistant strains of Staphylococcus aureus (MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. ). These studies have led to discoveries of unique compounds and DNA sequences that regulate crucial bacterial proteins. Life-threatening infections by newly evolving strains of resistant Staph staph n. Staphylococcus. staph adj. are becoming a significant public health problem. The Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. reports, "Staph bacteria are one of the most common causes of skin infection in the United States, and are a common cause of pneumonia and bloodstream infections...as many as 100,000 persons are hospitalized each year with MRSA infections, although only a small proportion of these persons have disease onset occurring in the community." The nation's annual cost associated with sepsis care is approximately $16.7 billion, and the average length of hospital stay is 19.6 days per patient. The incidence of sepsis is likely to increase because of an aging population and the widespread use of broad-spectrum antibiotics that cause pathogens to mutate mu·tate intr. & tr.v. mu·tat·ed, mu·tat·ing, mu·tates To undergo or cause to undergo mutation. [Latin m and become resistant. Dr. Malcolm Skolnick, CytoGenix President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented, "This patent application includes the results of many months of difficult scientific investigation and covers several discoveries that when combined produce powerful and safe DNA compounds against these very dangerous pathogens." CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 42 international or US pending patent applications claiming methods and materials in connection with this platform technology. SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion